This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Three primary studies were included in the review.
Methods of combining primary studies
The three studies provide estimates of different parameters and thus there was no need to combine the results except as separate inputs to the model.
Investigation of differences between primary studies
No investigation of differences between studies was discussed.
Results of the review
The reported results were as follows: the number of active IDUs in the United States, 1,000,000; the number of daily injections per IDU, 2.8; and the annual number of new HIV infections among IDUs, 19,000.
Methods used to derive estimates of effectiveness
The authors made assumptions to derive certain model inputs.
Estimates of effectiveness and key assumptions
Based on the proportion of IDU injections currently done with sterile syringes in cities with and without existing syringe exchange programs, the proportion nationally was assumed to take an intermediate value of 15%. The proportion of syringes made available but not used was assumed to be 10% (at every level of syringe availability). The proportion of new HIV infections among IDUs that were caused by injection behaviours was assumed to be 65%.
Measure of benefits used in the economic analysis
The measure of benefit was cases of HIV infection averted. This is a valid benefit measure which defines the analysis as a cost-effectiveness analysis.
Direct costs
The study was carried out from a societal perspective. A gross unit cost per syringe was calculated based on the assumed percentage of syringes distributed by syringe exchange programmes and through pharmacy sales. Differential costs were estimated (in a previously published study) for each of the two settings so, presumably, the costs included distribution as well as the cost of the syringes themselves. In this way both health service costs and out of pocket payments by IDUs who purchased syringes from pharmacies were included. The cost of syringe disposal was included in these estimates.
No discounting was applied as the study used a one-year time frame. The medical care component of the Consumer Price Index was used to convert the costs into June 1996 US dollars.
Indirect Costs
Productivity costs were not included.
Currency

US dollars ($).
Sensitivity analysis
The authors used threshold one-way sensitivity analysis to state that even if the cost of syringe provision were to increase threefold (from $0.44 to $1.40 per syringe), the full coverage programme would still be cost saving compared with the status quo. This incorporated sensitivity analysis about the percentage of syringes assumed to be dispensed by syringe exchange programmes as opposed to pharmacies, which would influence the average cost per syringe.
This result was also robust to halving the incidence of HIV infection among IDUs, and to decreasing the proportion of new infections caused by injection behaviours from 65.0% to 20.5%. 
Estimated benefits used in the economic analysis
Cost results
The annual programme cost of 100% coverage of previously unsterile injections was $423,336,522. The total cost of the comparator (status quo) was, by definition, $0. Total costs were calculated for levels of coverage from 0% to 100% in 10 percentage point increments.
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